Detection of prostate cancer index lesions with multiparametric magnetic resonance imaging (mp-MRI) using whole-mount histological sections as the reference standard

BJU International

Volumn 118, Issue 1, 2016, Pages 84-94

  Russo, Filippo ^a   Regge, Daniele ^a   Armando, Enrico ^a   Giannini, Valentina ^a   Vignati, Anna ^a   Mazzetti, Simone ^a   Manfredi, Matteo ^b   Bollito, Enrico ^b   Correale, Loredana ^c   Porpiglia, Francesco ^b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^c Medical Imaging Lab SpA   (Italy)

Author keywords

diagnostic imaging; magnetic resonance imaging; prostatic neoplasm

Indexed keywords

GADOBUTROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; GLEASON SCORE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VOLUME; PROSTATECTOMY; RADIOLOGIST; SENSITIVITY ANALYSIS; TUMOR VOLUME;

EID: 84975166795     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13234     Document Type: Article

References (34)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374–403
2. Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124–37
3. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–74
4. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239–46.
5. Postma R, Schröder FH. Screening for prostate cancer. Eur J Cancer 2005; 41: 825–33
6. Jones JS, Patel A, Schoenfield L, Rabets JC, Zippe CD, Magi-Galluzzi C. Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol 2006; 175: 485–8
7. Hong SK, Han BK, Lee ST et al. Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy. World J Urol 2009; 27: 271–6
8. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001; 166: 104–10
9. Tuma RS. New tests for prostate cancer may be nearing the clinic. J Natl Cancer Inst 2010; 102: 752–4
10. Porpiglia F, Russo F, Manfredi M et al. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy? J Urol 2014; 192: 60–6
11. Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61–71
12. Puech P, Rouvière O, Renard-Penna R et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy – prospective multicenter study. Radiology 2013; 268: 461–9
13. Park BK, Park JW, Park SY et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. AJR Am J Roentgenol 2011; 197: W876–81
14. Haffner J, Lemaitre L, Puech P et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011; 108: E171–8
15. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992; 70: 2313–8
16. Greene DR, Wheeler TM, Egawa S, Weaver RP, Scardino PT. Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Br J Urol 1991; 68: 499–509
17. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med 2009; 361: 1704–6
18. Liu W, Laitinen S, Khan S et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15: 559–65
19. Stamey TA, McNeal JM, Wise AM, Clayton JL. Secondary cancers in the prostate do not determine PSA biochemical failure in untreated men undergoing radical retropubic prostatectomy. Eur Urol 2001; 39(Suppl. 4): 22–3
20. Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 2003; 170: 459–63
21. Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int 2010; 106: 1607–11
22. Rosenkrantz AB, Deng FM, Kim S et al. Prostate cancer: multiparametric MRI for index lesion localization- a multiple-reader study. AJR Am J Roentgenol 2012; 199: 830–7
23. Barentsz JO, Richenberg J, Clements R et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22: 746–57
24. Futterer JJ. MR imaging in local staging of prostate cancer. Eur J Radiol 2007; 63: 328–34
25. Sciarra A, Barentsz J, Bjartell A et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011; 59: 962–77
26. Vargas HA, Akin O, Franiel T et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011; 259: 775–84
27. Kuhl CK, Mielcareck P, Klaschik S et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211: 101–10
28. Padhani AR, Gapinski CJ, Macvicar DA et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000; 55: 99–109
29. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71(Suppl. 3): 933–8
30. Nakashima J, Tanimoto A, Imai Y et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 2004; 64: 101–5
31. Le JD, Tan N, Shkolyar E et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol 2015; 67: 569–76
32. Ahmed HU, Arya M, Freeman A, Emberton M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol 2012; 13: 509–17
33. Merkle EM, Dale BM. Abdominal MRI at 3.0 T: the basics revisited. AJR Am J Roentgenol 2006; 186: 1524–32
34. Turkbey B, Merino MJ, Gallardo EC et al. Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging 2014; 39: 1443–8